Diagnosis and symptomatic treatment of migraine

Headache

Volumn 37, Issue SUPPL. 1, 1997, Pages

  Saper, Joel R ^a  

^a Michigan Hd Pain Neurologic Inst   (United States)

Author keywords

diagnosis; headache; migraine; treatment

Indexed keywords

BUTORPHANOL; DICHLORALPHENAZONE; DIHYDROERGOTAMINE; ERGOTAMINE TARTRATE; INDOMETACIN; ISOMETHEPTENE; KETOROLAC; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; SEROTONIN AGONIST; SUMATRIPTAN;

CLINICAL FEATURE; CONFERENCE PAPER; HUMAN; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; VERTIGO; VOMITING;

AFFECT; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATAXIA; ERGOTAMINE; HEADACHE; HUMANS; MIGRAINE DISORDERS; SEROTONIN AGONISTS; VISION;

EID: 0031024671     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 1993;43(suppl 3):S6-S10.
2. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA. 1992;267:64-69.
3. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resources and lost labour costs of migraine headaches in the US. PharmacoEconomics. 1992;2:67-76.
4. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993;33:29-35.
5. Lipton RB, Solomon S, Sheftell FD. Medical consultation for migraine: results from the AASH-Gallup survey. Poster presented at the 37th Annual Scientific Meeting of the American Association for the Study of Headache; June 23-25, 1995; Boston, Mass.
6. Celentano DD, Stewart WF, Lipton RB, et al. Medication use and disability among migraineurs: a national probability sample. Headache. 1992;32:223-228.
7. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992;152:1273-1278.
8. Lipton RB, Silberstein SD, Stewart WF. An update on the epidemiology of migraine. Headache. 1994;34:319-328.
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
10. Blau JN. Migraine prodromes separated from the aura: complete migraine. Br Med J. 1980;281:658-660.
11. Silberstein SD, Lipton RB. Overview of diagnosis and treatment of migraine. Neurology. 1994;44(suppl 7):S6-S16.
12. Saper JR, Silberstein SD, Gordon CD, Hamel RL. Medications used in the pharmacotherapy of headache. In: Handbook of Headache Management: A Practical Guide to Diagnosis and Treatment of Head, Neck, and Facial Pain. Baltimore: Williams & Wilkins; 1993:35-47.
13. Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry. 1960;23:23-32.
14. Wilkinson M. Clinical features of migraine. In: Rose FC, ed. Handbook of Clinical Neurology. New York: Elsevier; 1986:117-133.
15. Raskin NH. Headache. 2nd ed. New York: Churchill Livingstone; 1988.
16. Lipton RB, Solomon S, Newman LC, Sheftell FD. Gastrointestinal symptoms in migraine: results from the AASH-Gallup survey. Headache. 1995;35:563. Abstract.
17. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995;35:387-396.
18. Saper JR, Jones JM. Ergotamine dependency. Clin Neuropharmacol. 1986;9:244-256.
19. Granella E, D'Alessandro R, Mazzoni GC, et al. International Headache Society classification: interobserver reliability in the diagnosis of primary headache disorders. Cephalalgia. 1994;14:16-20.
20. Merikangas KR, Frances A. Development of diagnostic criteria for headache syndromes: lessons from psychiatry. Cephalalgia. 1993;13(suppl 12):34-38.
21. Stewart WF, Lipton RB, Schecter A. Diagnostic criteria for migraine: a validity study. Neurology. 1994;44(suppl 4):S11-S16.
22. Olesen J, Lipton RB. Migraine classification and diagnosis according to the International Headache Society. Neurology. 1994;44(suppl 4):S6.
23. Pfaffenrath V, Isler H. Evaluation of the nosology of chronic tension-type headache. Cephalalgia. 1993;13(suppl 12):60-62.
24. Silberstein SD, Lipton R, Solomon S, et al. Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache. 1994;34:1-7.
25. Solomon S, Lipton RB, Newman LC. Evaluation of chronic daily headache comparison to criteria for chronic tension-type headache. Cephalalgia. 1992;12:365-368.
26. Rasmussen BK, Jensen R, Olesen J. A population-based analysis of the diagnostic criteria of the International Headache Society. Cephalalgia. 1991;11:129-134.
27. Lance JW. Mechanism and Management of Headache. 4th ed. London: Buttersworth Scientific; 1982.
28. Saper JR. Headache Disorders: Current Concepts and Treatment Strategies. Littleton, Mass: Wright, PSG; 1983.
29. Robert AH. Behavioral management of headache. In: Dalessio DJ, Silberstein SD, eds. Wolff's Headache and Other Head Pain. 6th ed. New York: Oxford University Press; 1993:483-501.
30. Silberstein SD, Saper JR. Migraine: diagnosis and treatment. In: Dalessio DJ, Silberstein SD, eds. Wolff's Headache and Other Head Pain. 6th ed. New York: Oxford University Press; 1993:96-170.
31. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol. 1990;30:405-409.
32. Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A, et al. A double blind study of metoclopramide in the treatment of migraine attacks. J Neurol Neurosurg Psychiatry. 1980;43:369-371.
33. Volans GN. Migraine and drug absorption. Clin Pharmacokinet. 1978;3:313-318.
34. Tfelt-Hansen P, Lipton RB. Prioritizing acute pharmacotherapy. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993:359-362.
35. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Neurology. 1995;45:585-587.
36. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine with or without aura and status migrainosus. Neurology. 1995;45:577-584.
37. Baumel B. Migraine: a pharmacologic review with newer options and delivery modalities. Neurology. 1994;44(suppl 3):S13-S17.
38. Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol. 1986;30:331-334.
39. Peroutka SJ. The pharmacology of current anti-migraine drugs. Headache. 1990;30:5-11.
40. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
41. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-321.
42. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol. 1991;31:323-331.
43. Oral Sumatriptan Dose-Defining Study Group. Sumatriptan - an oral dose-defining study. Eur Neurol. 1991;31:300-305.
44. Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol. 1991;31:306-313.
45. Sargent J, Kirchner JR, Davis R, et al. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology. 1995;45:S10-S14.
46. Rapoport AM, Visser WH, Cutler NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology. 1995;45:1505-1509.
47. Akpunonu BE, Mutgi AB, Federman DJ, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med. 1995;25:464-469.
48. Hillis WS, Maclntyre PD. Sumatriptan and chest pain. Lancet. 1993;341:1564-1565.
49. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26:168-171.
50. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache. 1990;30:334-339.
51. Kanto J, Allonen H, Koski K, et al. Pharmacokinetics of dihydroergotamine in healthy volunteers and in neurological patients after a single intravenous injection. Int J Clin Pharmacol Ther Toxicol. 1981;19:127-130.
52. Sandoz Pharmaceuticals Corporation. Data on file, East Hanover, NJ.
53. Tfelt-Hansen P, Lipton RB. Dihydroergotamine. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993:323-327.
54. Winner P, Dalessio D, Mathew NT, et al. Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache. 1993;33:471-476.
55. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology. 1994;44:1587-1592.
56. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995-997.